Li Wen-Xuan, Yu Lu, Chi Jiang-Bo, Wang Ji-Peng, Liu Yong-Jun, Wang Chun-Hua, Zhang Meng, Hou Gui-Ge
School of Pharmacy, The Key Laboratory of Prescription Effect and Clinical Evaluation of State Administration of Traditional Chinese Medicine of China, Binzhou Medical University, Yantai, 264003, PR China.
Research and Development Department, Shandong Xianglong Medical Research Institute Co., Ltd, Yantai, 264005, PR China.
Eur J Med Chem. 2024 Mar 15;268:116284. doi: 10.1016/j.ejmech.2024.116284. Epub 2024 Feb 29.
NLRP3 inflammatory vesicles are a polymer of cellular innate immunity composed of a pair of proteins. The continuous activation of NOD-like receptor pyrin domain-containing protein 3 (NLRP3) inflammatory vesicles induces the occurrence and enhancement of inflammatory response. In this study, a series of 3, 4-dihydronaphthalene-1(2H)-one derivatives (DHNs, 6a-u, 7a-e, 8a-n) were synthesized and characterized by NMR and HRMS. We evaluated the cytotoxicity and anti-inflammatory activity of all compounds in vitro, and selected 7a substituted by 7-Br in A-ring and 2-pyridylaldehyde in C-ring as effective lead compounds. Specifically, 7a can block the assembly and activation of NLRP3 inflammasome by down-regulating the expression of NLPR3 and apoptosis-associated speck-like protein containing a CARD (ASC), and inhibiting the production of reactive oxygen species (ROS) and other inflammatory mediators. In addition, 7a inhibits the phosphorylation of inhibitor kappa B alpha (IκBα) and NF-κB/p65 and the nuclear translocation of p65, thereby inhibiting nuclear factor kappa-B (NF-κB) signaling. Molecular docking analysis confirmed that 7a could reasonably bind the active sites of NLRP3, ASC and p65 proteins. Therefore, 7a is predicted as a potential NLRP3 inflammatory vesicle inhibitor and deserves further research and development.
NLRP3炎性小体是由一对蛋白质组成的细胞固有免疫聚合物。含NOD样受体吡咯结构域蛋白3(NLRP3)炎性小体的持续激活诱导炎症反应的发生和增强。在本研究中,合成了一系列3,4-二氢萘-1(2H)-酮衍生物(DHNs,6a-u、7a-e、8a-n),并通过核磁共振和高分辨质谱对其进行了表征。我们在体外评估了所有化合物的细胞毒性和抗炎活性,并选择A环被7-溴取代且C环被2-吡啶甲醛取代的7a作为有效的先导化合物。具体而言,7a可通过下调NLPR3和含半胱天冬酶激活和招募结构域的凋亡相关斑点样蛋白(ASC)的表达,以及抑制活性氧(ROS)和其他炎症介质的产生,来阻断NLRP3炎性小体的组装和激活。此外,7a抑制抑制性κBα(IκBα)和核因子κB/p65的磷酸化以及p65的核转位,从而抑制核因子κB(NF-κB)信号传导。分子对接分析证实7a可合理结合NLRP3、ASC和p65蛋白的活性位点。因此,7a被预测为一种潜在的NLRP3炎性小体抑制剂,值得进一步研究和开发。